🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — August 19, 2026

The six filings from the S&P 500 Industrials stream reveal a sector characterized by significant insider profit-taking and leadership transitions, while balance sheet management remains defensive. Three separate insider sales events (Parker-Hannifin, RTX, Johnson Controls) totaling over $4.8 million suggest management is capitalizing on elevated valuations or signaling caution, particularly in the aerospace and fluid power sub-sectors. In contrast, Boeing's CFO tax withholding is routine and neutral. Honeywell's leadership reshuffle highlights a strategic push to sustain high-single-digit organic growth in Building Automation, while 3M's renewal of a $4.25 billion credit facility underscores a focus on liquidity and covenant discipline. No period-over-period financial trends (e.g., revenue growth or margin compression) were directly reported in these filings, limiting cross-company trend analysis, but the insider activity pattern is a notable sector-level signal.

6 high priority 6 total filings
· daily

US Material Events SEC 8-K Filings — August 19, 2026

The 50 filings reveal a dynamic market landscape with significant M&A activity, strategic financings, and leadership transitions. Key themes include a surge in SPAC-related transactions (Oceanhawk, Viking, Karman Line), aggressive capital raises via convertible notes (Datavault AI, Opendoor) and ATM offerings (FrontView, XCel), and notable M&A deals (Harte Hanks, Weave, Datavault AI). Period-over-period data shows mixed financial health: some companies like Ameresco reaffirm strong guidance, while others like Arrive AI face distress. Insider activity is limited but includes performance-based CEO grants (Unity, Envista) signaling alignment. Capital allocation trends show debt refinancing (Newell, Griffon) and balance sheet strengthening (Saratoga). Forward-looking catalysts include clinical trial readouts (Longeveron) and M&A closings (Destination XL). Overall, the market is active with both opportunities and risks, particularly in high-growth tech and SPAC sectors.

50 high priority 50 total filings
· daily

Insider Trading Pulse — August 19, 2026

The August 19, 2026, insider trading digest reveals a pronounced bearish tilt, with 22 sell transactions from corporate insiders totaling over $27 million, dwarfing $3.5 million in insider buys. The most concentrated selling occurred at Sea Ltd, where five top executives (CFO, COO, Presidents) collectively cashed out over $4.7 million under 10b5-1 plans, signaling a potential peak sentiment in the tech sector. Conversely, a few high-conviction insider purchases stand out, including a $1.44 million buy by CCH Holdings' Chairman/CEO/COO and a $207K purchase by American Coastal Insurance's COO, suggesting deep value plays. The data shows a clear divergence: growth/tech insiders are taking profits, while insiders at small/mid-cap value and special situation companies are deploying capital. Key period-over-period trends are limited in this single-day snapshot, but the sheer volume of selling at Sea Ltd and Marathon Petroleum ($2.58M) warrants close monitoring for sector-wide de-risking.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — August 19, 2026

The August 19, 2026 batch of Dow 30 filings is dominated by insider transactions, with three notable sell-side events from senior executives at American Express, Sherwin-Williams, and Chevron, totaling over $11M in realized proceeds. While these sales are partially explained by option exercises and tax planning, the sheer volume and proximity raise a cautionary flag on management conviction at these specific companies. In contrast, Amazon's insider sale was executed under a pre-arranged 10b5-1 plan, reducing its signal value. The two operational filings (3M and Honeywell) are neutral, focusing on routine credit facility renewals and leadership transitions, respectively. No period-over-period financial trends or forward-looking guidance changes were present in this batch, limiting the ability to identify portfolio-level growth or margin trends. The key takeaway is a moderate insider selling bias across the industrials and financials sectors, warranting closer scrutiny of upcoming earnings calls for these names.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 19, 2026

The August 19, 2026 corporate distress landscape is dominated by acute delisting risks at two micro-cap biotech firms, Skye Bioscience and OSR Holdings, both of which received Nasdaq Staff Determinations. Skye faces a fundamental solvency crisis with negative stockholders' equity (-$497K vs. a $2.5M minimum), while OSR faces an imminent trading suspension on August 26 due to a chronic bid price deficiency, despite a massive, anomalous trading spike (370M shares on Aug 17). In contrast, Mereo BioPharma has been granted a second 180-day extension to cure its bid price deficiency, providing a longer runway until February 2027. The fourth filing, Trio-Tech International, is a voluntary, non-distressed listing transfer from NYSE American to Nasdaq, representing a neutral, administrative event. The key portfolio-level pattern is a bifurcation between companies with fundamental equity insolvency (Skye) and those with purely market-price-driven compliance issues (OSR, Mereo), with the former presenting a materially higher risk of permanent delisting. Insider activity data was absent from all filings, limiting conviction signals, but the forward-looking data creates a clear catalyst calendar of hearings and deadlines.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — August 19, 2026

This digest of 50 SEC filings from August 19, 2026, reveals a market sharply bifurcated between distressed situations and strategic M&A. A cluster of 10 SPAC filings, including a $200 million IPO (Karman Line) and several delistings (Artius II, Xos warrants), highlights the ongoing churn in the blank-check sector. The most critical developments are the near-completion of the $77/share acquisition of Forte Biosciences by argenx, a high-risk delisting notice for Skye Bioscience, and a massive $1.0 billion token deal for Flora Growth Corp. On the distressed side, three Indian companies (AGS Transact, Setubandhan, Zicom) are in active insolvency, while two iShares ETFs were voluntarily liquidated. Insider activity is notably absent across the filings, but forward-looking data points to several key catalysts, including shareholder votes and compliance deadlines. The overarching theme is capital allocation under pressure: companies are either aggressively pursuing transformative M&A, winding down, or fighting for survival.

50 high priority 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — August 19, 2026

The four filings from S&P 500 Consumer Discretionary constituents reveal a sector bifurcating between off-price and home improvement winners and e-commerce/retail laggards. TJX Companies delivered a standout quarter with 24% EPS growth and raised full-year guidance, though its core Marmaxx segment and Canada business showed deceleration, signaling potential saturation risk. Lowe's reported a fifth consecutive quarter of positive comparable sales but saw operating margin contract 81 bps and narrowed its full-year outlook, reflecting persistent DIY headwinds and tariff uncertainty. Insider activity at Amazon showed a top executive selling nearly $500K in stock under a 10b5-1 plan, which, while pre-planned, adds to a pattern of insider selling at the company. Marriott's filing was a routine tax withholding event with no actionable signal. The overarching theme is that off-price retail is gaining share, while home improvement faces a demand trough, and e-commerce insiders are reducing exposure.

2 high priority 2 medium 4 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — August 19, 2026

The three S&P 500 Healthcare filings for August 19, 2026, present a mixed picture: insider selling at Centene and Intuitive Surgical contrasts with a neutral leadership change at Baxter. Centene's General Counsel sold a material $3.1M stake, signaling potential bearish sentiment from a key insider, while Intuitive Surgical's EVP executed a small, pre-planned sale of $90K, which is less concerning. Baxter's appointment of a new CFO with strong transformation experience and reaffirmed full-year guidance provides stability. No period-over-period financial trends or forward-looking guidance changes were available from these filings, limiting trend analysis. The primary actionable intelligence centers on insider activity and corporate governance signals, with Baxter's leadership transition being the most significant event for future strategic direction.

3 high priority 3 total filings
· daily

US Earnings Financial Results SEC Filings — August 19, 2026

The 50 filings for the period ending August 19, 2026, reveal a deeply bifurcated market. While a handful of established companies like Analog Devices and Brinker International posted strong, operationally-driven growth, the vast majority of filers—particularly small-cap and micro-cap entities—are reporting severe financial distress. A dominant theme is the 'revenue mirage' where top-line growth is driven by one-time gains, acquisitions, or non-cash items, masking underlying operational deterioration. This is exemplified by Atlantic International Corp., whose revenue surged 211% from an acquisition while its net loss ballooned to $86.4M. The data also highlights a 'cash crunch' crisis, with 10+ companies reporting critically low or zero cash balances, including Nutra Pharma Corp and Kinetic Seas Inc. Insider trading activity was notably absent from the enriched data, but forward-looking statements from Ocean Power Technologies include a material going concern warning, a significant red flag. Capital allocation trends are mixed, with Flexsteel Industries aggressively buying back stock while others like KALA BIO are forced into reverse stock splits to maintain listings. The overall picture is one of extreme caution, where investors must rigorously distinguish between genuine, sustainable growth and accounting-driven illusions.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — August 19, 2026

The six proxy filings reveal a bifurcated market: two high-materiality corporate actions (Columbus Acquisition's SPAC merger and Hancock Park's liquidation) contrast with four routine governance documents. Columbus Acquisition's merger with WISeSat.Space carries significant uncertainty due to undisclosed cash and redemption levels, while Hancock Park's wind-down signals a definitive exit. BayFirst Financial and Advent Convertible & Income Fund present standard proposals with no major financial or strategic changes. OneMedNet's reverse stock split and equity plan increase suggest a proactive balance sheet restructuring. Howard Hughes Holdings stands out with positive sentiment, driven by Pershing Square's $900M investment and strong 2025 results, indicating a transformative period. Across the portfolio, no clear sector-wide trends emerge, but the mix of liquidation, merger, and routine governance underscores diverse corporate lifecycles. Key period-over-period data is limited, but forward-looking events (meetings in September and October) provide a catalyst calendar for investors.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — August 19, 2026

The IPO pipeline this period is thin with only two filings, but they represent divergent paths: a speculative renewable fuels IPO (XCF Global) and a routine corporate redomiciling (Genpact). XCF Global's S-1 reveals a high-risk growth story with revenue surging 52.9% YoY but persistent net losses and a deep accumulated deficit of $24.4M, signaling a capital-intensive venture with no path to profitability yet. Genpact's S-4 is a non-offering, administrative domestication with no financials and neutral sentiment, offering no trading or valuation signals. The overarching theme is a lack of high-quality, profitable IPOs entering the pipeline, with XCF's mixed sentiment and material financial red flags suggesting caution for yield-oriented investors. The data underscores a razor-thin pipeline where most activity is structural (redomiciling) rather than capital formation, reinforcing a risk-off posture toward new issuances until more mature, cash-flow-positive filers emerge.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — August 19, 2026

The August 19, 2026 trading suspension landscape is dominated by two acute delisting events (Skye Bioscience and OSR Holdings) that signal severe financial distress and imminent liquidity crises for micro-cap biotech and health companies. Skye Bioscience faces a Nasdaq delisting due to negative stockholders' equity (-$497K vs. $2.5M minimum), while OSR Holdings will be suspended from trading on August 26 after failing to maintain the $1.00 bid price for two consecutive compliance periods. In contrast, Mereo BioPharma has been granted a second 180-day extension (until Feb 2027) to regain compliance, and Trio-Tech International is voluntarily transferring its listing from NYSE American to Nasdaq, representing a neutral, non-distressed event. The key portfolio-level pattern is a bifurcation between companies with viable paths to compliance (Mereo, Trio-Tech) and those facing near-certain delisting (Skye, OSR). No insider trading activity, capital allocation changes, or forward-looking guidance were reported in any of the filings, limiting the depth of trend analysis but highlighting the reactive, compliance-driven nature of these events.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — August 19, 2026

This digest of 28 filings reveals a significant wave of leadership transitions across US public companies, with a notable concentration of CFO changes and board refreshment events. The period is marked by a distinct pattern of performance-based compensation restructuring, particularly in the technology and biotech sectors, where companies like Unity Software and Revelation Biosciences are tying executive pay to aggressive stock price and market capitalization milestones. A key portfolio-level trend is the shift toward enhanced governance, exemplified by Granite Ridge Resources' declassification from a 'controlled company' and the appointment of independent directors at multiple firms. While most transitions appear orderly, the departure of Ameresco's CFO alongside its General Counsel within the same week raises a succession risk flag. The data also shows a strong emphasis on aligning executive incentives with long-term shareholder value creation, with several companies implementing significant equity awards tied to operational and market performance hurdles. No material period-over-period financial comparisons were available in these filings, as they are primarily focused on corporate governance and personnel changes, but forward-looking statements from Ameresco and Baxter indicate reaffirmed guidance, providing stability amidst the leadership changes.

28 high priority 28 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 19, 2026

This digest covers 28 filings from August 19, 2026, focused on USA board room changes, with 19 new filings and 9 for context. The period is dominated by routine director appointments and CFO transitions, with a notable cluster of executive compensation changes tied to performance metrics and retention. Key themes include a wave of CFO changes across diverse sectors (Ameresco, Sera Prognostics, Baxter, United Community Banks, Core Natural Resources, Longeveron, PDS Biotechnology), suggesting a broader talent reshuffle. Several companies are using performance-based equity awards (Unity Software, Revelation Biosciences, Envista Holdings) to align management with shareholder value creation, while others are strengthening board independence (Granite Ridge Resources, AMD). No significant period-over-period financial trends are available as most filings are governance-related, but forward-looking data points to a catalyst in September 2026 for Longeveron's Phase 2b trial results. Overall, the filings indicate a healthy governance environment with proactive succession planning, but the high volume of CFO departures warrants monitoring for potential operational disruptions.

28 high priority 28 total filings
· daily

USA Insider Trading Pulse — August 19, 2026

The August 19, 2026 insider trading pulse reveals a predominantly bearish sentiment with significant insider selling across multiple sectors, totaling over $30 million in disclosed transactions. The most concentrated selling occurred at Sea Ltd, where four top executives (President, CFO, COO, CCO) collectively sold over $4.5 million in stock, all under Rule 10b5-1 plans, suggesting pre-planned portfolio diversification rather than a reactive negative signal. The energy sector showed notable insider selling, with a 10% owner at PBF Energy selling $9 million and Marathon Petroleum's Chief Legal Officer selling $2.6 million after exercising options. However, a strong bullish counter-signal emerged from CCH Holdings Ltd, where the Chairman/CEO/COO made a $1.44 million open-market purchase, representing the most significant insider buying in this batch. The data shows a clear pattern of C-suite option exercises followed by immediate sales, particularly in the technology and energy sectors, while several small-cap and micro-cap companies saw insider buying at current levels, indicating potential value opportunities. The overall market signal is mixed, with insider selling concentrated in larger-cap names and buying focused on smaller, potentially undervalued companies.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 19, 2026

The August 19, 2026, US M&A digest reveals a market bifurcated between high-conviction, value-creating acquisitions and speculative SPAC formations. The most actionable signal is **Datavault AI's (DVLT)** acquisition of NYIAX, which provides a clear path to its ambitious $200M revenue target, contrasting sharply with the non-operational SPACs. A dominant theme is the emergence of a 'SPAC 2.0' ecosystem, with five SPACs (Oceanhawk, Futurewave, Pelican II, OceanLight, Karman Line) all sharing common backers (HBM Group/Luminark), suggesting a coordinated strategy to deploy capital in specific sectors, particularly aerospace. The most significant risk is the lack of disclosed financials in several key deals, including the $1B token transaction by **Flora Growth (FLGC)** and the DVLT acquisition, creating valuation uncertainty. The resignation of two directors at **Ocean Capital Acquisition Corp** is a minor red flag, but the appointment of experienced independent directors mitigates the concern. Overall, the digest points to a market where investors should favor companies with disclosed financials and clear operational synergies, like DVLT and **Earth Science Tech (ETST)**, while treating the SPAC cohort with caution until targets are announced.

14 high priority 14 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 19, 2026

This overnight filing cycle is dominated by a major M&A development in the protein sector, with JBS N.V. making a non-binding proposal to acquire the remaining ~18% of Pilgrim's Pride it does not own. The implied valuation offers no premium, creating a potential arbitrage opportunity but also signaling a lack of urgency from the buyer. Insider selling is the most prevalent theme, with notable disposals from executives at Roivant Sciences, Corpay, and Veradermics, suggesting management is taking profits at elevated levels. A significant governance battle is unfolding at Better Home & Finance, where the CEO's attempt to remove directors has led to a lawsuit, creating high uncertainty. On the positive side, a key regulatory condition (HSR waiting period) was cleared for argenx's acquisition of Forte Biosciences, moving that deal closer to completion. The filing set also includes a delisting notice for Skye Bioscience due to negative equity, and a large convertible note issuance by Datavault AI, indicating financial distress. Overall, the market is presented with a mix of high-stakes M&A, insider profit-taking, and corporate governance risks, with few clear bullish signals from operational results.

37 high priority 13 medium 50 total filings
· daily

Biotech Small-Cap Approvals — August 18, 2026

The August 18, 2026, digest covers five FDA approvals, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion), including two NMEs and three biosimilars. The dominant therapeutic area is neurology (tau PET imaging) and oncology (multiple myeloma), with the highest-conviction signal being Bristol Myers Squibb’s IBERDOMIDE (ZENBEXUS) — an NME granted Priority Review and Orphan Drug designation for multiple myeloma, signaling a potential blockbuster launch. A key risk is the lack of commercial data (peak sales, exclusivity, pricing) for all approvals, limiting near-term revenue visibility. The two NME approvals (FLORQUINITAU F18 and IBERDOMIDE) are bullish signals, while the three biosimilar approvals (PITOLISANT x2, FIDAXOMICIN) are neutral, as they lack competitive context against originators.

5 total filings
· daily

NME Blockbuster Approvals — August 18, 2026

The August 18, 2026 approval period featured a single NME approval—Bristol Myers Squibb’s iberdomide (ZENBEXUS)—granted under Priority Review and Orphan Drug status, signaling a high-conviction bullish event for the sponsor. This approval reinforces BMS’s hematology pipeline strength but lacks immediate commercial data (peak sales, pricing, exclusivity not disclosed), limiting near-term revenue visibility. The absence of biosimilar or label expansion approvals narrows the period’s therapeutic focus to oncology/rare disease. Key watch item: post-launch payer coverage and competitive dynamics in the multiple myeloma space, where iberdomide enters a crowded field with established Celgene/BMS assets (lenalidomide, pomalidomide) and newer entrants (e.g., Johnson & Johnson’s Tecvayli).

1 total filings
· daily

Orphan Drug Approvals — August 18, 2026

The single approval in this period is Bristol Myers Squibb's iberdomide (ZENBEXUS), an NME for an undisclosed orphan indication, granted Priority Review and Orphan Drug designation. This is a high-conviction bullish signal for BMS, as the drug benefits from 7-year orphan exclusivity and potential premium pricing, though the commercial opportunity remains undisclosed. The approval reinforces BMS's execution capability in rare disease drug development, but the lack of disclosed indication size or sales estimates limits full investment thesis validation. No biosimilars or label expansions were approved, making this a focused, sponsor-specific event.

1 total filings